<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01272557</url>
  </required_header>
  <id_info>
    <org_study_id>SoraDox</org_study_id>
    <nct_id>NCT01272557</nct_id>
  </id_info>
  <brief_title>Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial</brief_title>
  <acronym>SoraDox</acronym>
  <official_title>Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PD Dr. med. Matthias Dollinger</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Martin-Luther-Universität Halle-Wittenberg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open-label, multicenter phase IIB trial in order to&#xD;
      determine time to progression of the combination therapy sorafenib plus doxorubicin against&#xD;
      standard-of-care sorafenib in advanced HCC not amenable to non-systemic treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP) according to RECIST 1.1 criteria</measure>
    <time_frame>The follow-up period ends 12 months after enrolment of the last patient (end of study visit of the last patient unless he died earlier</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Assessment of overall survival (OS) of disease control rate (CR, PR, SD) to RECIST 1.1 criteria and to EASL criteria • Assessment of safety and quality of life (FACT-Hep) and potential of biomarkers to predict the tumor response</measure>
    <time_frame>The follow-up period ends 12 months after enrolment of the last patient (end of study visit of the last patient unless he died earlier).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Liver Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib 400 mg bid (oral) continuously</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 400 mg bid (oral) continuously until progression or unacceptable toxicity).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During trial therapy period in Arm-A treated patients will receive doxorubicin infusion with 60mg/m² on day 1 every 21 days for maximum of 18 weeks (or 6 cycles) until a maximal dose of 360mg/m² are reached. Sorafenib 400mg bid (oral) will be administered from day 3-19 every 21 days during the trial therapy period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).</description>
    <arm_group_label>q22d: Doxorubicin 60 mg/m2 i.v d1, Sorafenib 400 mg bid d3-19</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 400 mg bid (oral) continuously</description>
    <arm_group_label>Sorafenib 400 mg bid (oral) continuously</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-resectable locally advanced or metastasized HCC&#xD;
&#xD;
          -  Subjects must have at least one tumor lesion that meets both of the following&#xD;
             criteria:&#xD;
&#xD;
          -  the lesion can be accurately measured in at least one dimension according to RECIST&#xD;
             1.1&#xD;
&#xD;
          -  the lesion has not been previously treated with local therapy (such as surgery,&#xD;
             radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency&#xD;
             ablation, percutaneous ethanol injection or cryoablation)&#xD;
&#xD;
          -  Subjects who have received local therapy (such as surgery, radiation therapy, hepatic&#xD;
             arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol&#xD;
             injection or cryoablation) are eligible, provided that they have a target lesion which&#xD;
             has not been subjected to local therapy. Local therapy must be completed at least 4&#xD;
             weeks prior to the baseline scan.&#xD;
&#xD;
          -  Confirmation of disease by histology&#xD;
&#xD;
          -  Liver function: Child Pugh stage A/B (5-7 points) only&#xD;
&#xD;
          -  Tumor stage: BCLC stage C (or better)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to screening and within 4 weeks&#xD;
             before start of treatment:&#xD;
&#xD;
          -  Hemoglobin ≥ 9.0 g/dl&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.500/mm3&#xD;
&#xD;
          -  Platelet count ≥ 70.000/μl&#xD;
&#xD;
          -  Total bilirubin ≤ 3 mg/dl&#xD;
&#xD;
          -  ALT and AST ≤ 5 x upper limit of normal&#xD;
&#xD;
          -  Alkaline phosphatase &lt; 4 x upper limit of normal&#xD;
&#xD;
          -  PT-INR/PTT &lt; 1.5 x upper limit of normal [Patients who are being therapeutically&#xD;
             anticoagulated with an agent such as warfarin, phenprocoumon or heparin will NOT be&#xD;
             allowed to participate]&#xD;
&#xD;
          -  Serum creatinine ≤ 1.5 x upper limit of normal&#xD;
&#xD;
          -  Signed and dated informed consent before start of any study specific procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients eligible for resection or transplantation&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct in primary site or histology from the&#xD;
             cancer being evaluated in this study. However cervical carcinoma in situ, treated&#xD;
             basal cell carcinoma, superficial bladder tumors (Ta, Tis and T1) or any cancer&#xD;
             curatively treated &gt; 3 years prior to entry is permitted&#xD;
&#xD;
          -  Serious myocardial dysfunction: defined as absolute left ventricular ejection fraction&#xD;
             (LVEF) &lt; 50%, instable coronaropathy (MI more than 6 mo prior to study entry is&#xD;
             allowed), cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or&#xD;
             digoxin are permitted)&#xD;
&#xD;
          -  Inadequately controlled hepatic complications (varices, encephalopathy)&#xD;
&#xD;
          -  Untreated active Hepatitis B including HBs-Ag carriers; patients should be started on&#xD;
             (prophylactic) anti-viral medication even without current viral replication&#xD;
&#xD;
          -  Concomitant therapy with interferon (e.g. Hepatitis B/C) during study phase&#xD;
&#xD;
          -  Uncontrolled arterial hypertension with systolic blood pressure &gt;160 mmHg or diastolic&#xD;
             blood pressure &gt; 90 mm Hg despite optimal treatment&#xD;
&#xD;
          -  Known history of HIV infection&#xD;
&#xD;
          -  Active clinically serious infections (&gt; grade 2 NCI-CTC version 3.0)&#xD;
&#xD;
          -  Symptomatic metastatic brain or meningeal tumors (unless the patient is &gt; 6 months&#xD;
             from definitive therapy, has a negative imaging study within 4 weeks of study entry&#xD;
             and is clinically stable with respect to the tumor at the time of study entry)&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication (such as steroids or&#xD;
             anti-epileptics)&#xD;
&#xD;
          -  History of organ allograft&#xD;
&#xD;
          -  Patients with evidence or history of bleeding diathesis&#xD;
&#xD;
          -  Thrombotic or embolic events within the last 6 months&#xD;
&#xD;
          -  Serious non-healing wound, fracture, or ulcer&#xD;
&#xD;
          -  Pregnant or breast-feeding patients. Women of childbearing potential must have a&#xD;
             negative pregnancy test performed within 7 days of the start of treatment. Women&#xD;
             enrolled in this trial must use adequate barrier birth control measures during the&#xD;
             course of the trial for at least 6 months after last administration of doxorubicin and&#xD;
             2 months after the last administration of sorafenib.&#xD;
&#xD;
          -  Severe concomitant disease or psychiatric disorders&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patient's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Known severe hypersensitivity to sorafenib, doxorubicin or any of the excipients&#xD;
&#xD;
          -  Patients unable to swallow oral medications&#xD;
&#xD;
          -  Incompliance / contraindications against study medication&#xD;
&#xD;
        Excluded therapies and medications, previous and concomitant:&#xD;
&#xD;
          -  Previous systemic therapy for HCC&#xD;
&#xD;
          -  Anticancer chemotherapy or immunotherapy or targeted therapy (except study medication)&#xD;
             during the study or within 4 weeks of study entry.&#xD;
&#xD;
          -  Radiotherapy during study or within 3 weeks of start of study drug. (Palliative&#xD;
             radiotherapy will be allowed). Major surgery within 4 weeks of start of study&#xD;
&#xD;
          -  Autologous bone marrow transplant or stem cell rescue within 4 months of study&#xD;
&#xD;
          -  Use of biologic response modifiers, such as G-CSF, within 3 week of study entry.&#xD;
             [G-CSF and other hematopoietic growth factors may be used in the management of acute&#xD;
             toxicity such as febrile neutropenia when clinically indicated or at the discretion of&#xD;
             the investigator, however they may not be substituted for a required dose reduction.]&#xD;
             [Patients taking chronic erythropoietin are permitted provided no dose adjustment is&#xD;
             undertaken within 2 months prior to the study or during the study]&#xD;
&#xD;
          -  Patients receiving anticoagulation therapy or ASS &gt;100 mg/d&#xD;
&#xD;
          -  Investigational drug therapy outside of this trial during or within 4 weeks of study&#xD;
             entry&#xD;
&#xD;
          -  Prior exposure to the study drug.&#xD;
&#xD;
          -  Any St. John's wort containing remedy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik, Heinrich-Heine-Universität</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Martin-Luther-University Halle-Wittenberg</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>D-06099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlande</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ortenau Klinikum Lahr-Ettenheim</name>
      <address>
        <city>Lahr</city>
        <zip>77933</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04013</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>January 6, 2011</study_first_submitted>
  <study_first_submitted_qc>January 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2011</study_first_posted>
  <last_update_submitted>March 31, 2014</last_update_submitted>
  <last_update_submitted_qc>March 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Martin-Luther-Universität Halle-Wittenberg</investigator_affiliation>
    <investigator_full_name>PD Dr. med. Matthias Dollinger</investigator_full_name>
    <investigator_title>PD. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>HCC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

